J. Harlan

发表

Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis

R. Meadows, S. Fesik, C. Thompson, 1997, Science.

Structure of MurF from Streptococcus pneumoniae co‐crystallized with a small molecule inhibitor exhibits interdomain closure

P. Hajduk, K. Longenecker, V. Stoll, 2005, Protein Science.

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

R. Meadows, S. Fesik, S. Muchmore, 1996, Nature.

Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

P. Keller, J. Harlan, V. Nimmrich, 2005, Journal of neurochemistry.

Non-invasive characterization of β-amyloid1-40 vasoactivity by functional magnetic resonance imaging in mice

M. Schmidt, F. Luo, G. Fox, 2008, Neuroscience.

Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization.

Jean M. Severin, Rolf Wagner, Vincent S Stoll, 2004, Journal of medicinal chemistry.

NMR Structure and Mutagenesis of the N-Terminal Dbl Homology Domain of the Nucleotide Exchange Factor Trio

Hong Wang, R. Meadows, E. Olejniczak, 1998, Cell.

Protein fragmentation via liquid chromatography-quadrupole time-of-flight mass spectrometry: the use of limited sequence information in structural characterization.

Richard D. Smith, S. Dorwin, K. Walter, 2005, Analytical biochemistry.

forms an inactivating dimer with Bcl-XL . Bad is a BH 3 domain-containing protein

S. Fesik, C. Thompson, J. Harlan, 1997 .

A potent erythropoietin-mimicking human antibody interacts through a novel binding site.

V. Stoll, D. Egan, R. Simmer, 2007, Blood.

Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo

J. C. Pratt, S. Fesik, K. Ravichandran, 1997, Molecular and cellular biology.

Binding Affinities of Tyrosine-phosphorylated Peptides to the COOH-terminal SH2 and NH-terminal Phosphotyrosine Binding Domains of Shc (*)

S. Fesik, Ming-Ming Zhou, K. Ravichandran, 1996, The Journal of Biological Chemistry.

Empowering therapeutic antibodies with IFN-α for cancer immunotherapy

Tzu-Hsuan Huang, A. Shoemaker, U. Ladror, 2019, PloS one.

On-column ligand exchange for structure-based drug design: a case study with human 11β-hydroxysteroid dehydrogenase type 1.

K. Longenecker, R. Judge, J. Harlan, 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

Rocky Mountain spotted fever. Serological evidence of previous subclinical infection in children.

C. McCall, J. Abramson, J. Harlan, 1982, American journal of diseases of children.

Recombinant kringle 5 from plasminogen antagonises hepatocyte growth factor-mediated signalling.

P. Ansell, D. Davidson, J. Harlan, 2010, European journal of cancer.

Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design

C. Jakob, T. Ghayur, E. DiGiammarino, 2011, mAbs.

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

V. Stoll, T. Holzman, S. Muchmore, 2005, Anti-cancer drugs.

Driving affinity selection by centrifugal force.

D. Egan, T. Holzman, U. Ladror, 2003, Assay and drug development technologies.

Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195.

K. Swinger, Eric F. Johnson, N. Soni, 2013, ACS medicinal chemistry letters.

Magnesium-dependent adenosine triphosphatase as a marker enzyme for the plasma membrane of human polymorphonuclear leukocytes

C. McCall, J. Harlan, D. Iverson, 1977, Infection and immunity.

Preparation and characterization of nitrilotriacetic-acid-terminated self-assembled monolayers on gold surfaces for matrix-assisted laser desorption ionization-time of flight-mass spectrometry analysis of proteins and peptides.

Jean M. Severin, Richard D. Smith, Jieyi Wang, 2005, Analytical biochemistry.

Structure and ligand recognition of the phosphotyrosine binding domain of Shc

A. Petros, R. Meadows, E. Olejniczak, 1995, Nature.

Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate.

P. Hajduk, S. Fesik, H. Yoon, 1995, Biochemistry.

Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate

P. Hajduk, S. Fesik, H. Yoon, 1994, Nature.

The BH3 Domain of Bcl-xS Is Required for Inhibition of the Antiapoptotic Function of Bcl-xL

John E. Harlan, Ameeta Kelekar, Stephen W. Fesik, 1999, Molecular and Cellular Biology.

A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity

D. Song, A. Wahl, D. Chao, 2019, Cancer Immunology Research.

NMR studies of the anti-apoptotic protein Bcl-xL in micelles.

E. Olejniczak, S. Fesik, S. Betz, 2000, Biochemistry.

Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL

S. Fesik, C. Thompson, J. Harlan, 1997, Molecular and cellular biology.

The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain

Jonathan Greer, J. Greer, J. Gustafsson, 2003, Journal of Biological Chemistry.

From Bacterial Genomes to Novel Antibacterial Agents: Discovery, Characterization, and Antibacterial Activity of Compounds that Bind to HI0065 (YjeE) from Haemophilus influenzae

P. Hajduk, K. Comess, Liping Yu, 2007, Chemical biology & drug design.

Structural characterization of a soluble amyloid beta-peptide oligomer.

P. Hajduk, P. Richardson, Liping Yu, 2009, Biochemistry.

Rubella susceptibility in sixth graders: effectiveness of current immunization practice.

J. Harlan, J. Abramson, M. R. Lawless, 1980, Pediatrics.

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

John E. Harlan, Ramesh Iyer, Yan Shi, 2011, Clinical Cancer Research.

A potent erythropoietin mimic human antibody interacts through a novel binding site Running titile: EPOR AB ACTIVATES THROUGH A NOVEL BINDING SITE

V. Stoll, D. Egan, R. Simmer, 2007 .

Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease

P. Keller, J. Harlan, V. Nimmrich, 2005 .

Variants in Apaf-1 segregating with major depression promote apoptosome function

Jean M. Severin, T. Holzman, V. Abkevich, 2006, Molecular Psychiatry.

NMR Structures of Proteins Involved in Signal Transduction

T. Logan, R. Meadows, E. Olejniczak, 1996 .

Observations of Xyleborus affinis Eichhoff (Coleoptera:Curculionidae:Scolytinae) in Central Michigan

J. Harlan, R. Bowker, M. Bunce, 2015 .

Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.

D. Kempf, J. Randolph, K. Marsh, 2009, Bioorganic & medicinal chemistry letters.

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches

D. Egan, R. Judge, L. Benatuil, 2019, BMC Molecular and Cell Biology.

Cancer Therapy : Preclinical Iniparib Nonselectively Modi fi es Cysteine-Containing Proteins in TumorCells and IsNot a Bona Fide PARP Inhibitor

P. Ellis, Eric F. Johnson, N. Soni, 2012 .

PULSE SPR: A High Throughput Method to Evaluate the Domain Stability of Antibodies.

E. DiGiammarino, J. Harlan, W. Stine, 2018, Analytical chemistry.

The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain RU-486 INDUCES A TRANSCONFORMATION THAT LEADS TO ACTIVE ANTAGONISM*

Jie Yang, J. Greer, S. Muchmore, 2003 .

Globular amyloid b-peptide 1 ) 42 oligomer ) a homogenous and stable neuropathological protein in Alzheimer ’ s disease

P. Keller, J. Harlan, V. Nimmrich, 2005 .

Preparation of Phgsphatioyll2-3Hjinositgl from Yeast Grown in Medium Containing N;Yol2-3Hjinositol

J. Harlan, G. Graff, Nabeel Nanas, 1982 .

The use of cyclic peptide antigens to generate LRP8 specific antibodies

D. Egan, F. Gizatullin, J. Harlan, 2023, Frontiers in Drug Discovery.

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches

D. Egan, R. Judge, L. Benatuil, 2019, BMC Molecular and Cell Biology.

Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery

Kevin Harris, Kent D. Stewart, Kevin Steffy, 2007, J. Comput. Aided Mol. Des..

Calibration of size-exclusion chromatography: use of a double Gaussian distribution function to describe pore sizes.

P. Loll, R. Garavito, J. Harlan, 1995, Analytical biochemistry.